- Home
- CNTB vs MIST Comparison
CNTB vs MIST Comparison
Compare CNTB & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | MIST |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 163.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTB | MIST |
|---|---|---|
| Price | $2.33 | $2.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $8.50 | $8.50 |
| AVG Volume (30 Days) | 314.4K | ★ 9.5M |
| Earning Date | 03-31-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $762,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $38,289.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $0.63 |
| 52 Week High | $3.28 | $3.06 |
Technical Indicators
Market Signals| Indicator | CNTB | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 42.49 |
| Support Level | $2.03 | $2.00 |
| Resistance Level | $2.38 | $2.22 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | -0.06 | -0.09 |
| Stochastic Oscillator | 36.36 | 37.59 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).